CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia...http://www.google.de/patents/US7351803?utm_source=gb-gplus-sharePatent US7351803 - CD16A binding proteins and use for the treatment of immune disorders
